Deutsch
English
Русский

Universitätsklinikum Würzburg 

ZIM (Zentrum Innere Medizin)
Haus A3/A4 

Oberdürrbacherstr. 6

97080 Würzburg

ZOM / ZIM

Studien - HIV/AIDS

TMC114: Early access of TMC114 in combination with low dose ritonavir (RTV) and other antiretrovirals in highly treatment-experienced HIV-1 infected subjects with limited to no treatment options.

MK-0518: Early access of MK-0518 (HIV-Integrase Inhibitor) in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options.

ESPRIT: A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant IL-2 in Patients With HIV-1 Infection and CD4 Cell Counts ≥ 300/µl (Multicenterstudie, Sponsor: NIH/USA)

SMART: A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy. (Multicenterstudie, Sponsor: NIH/USA)

PREDICT-1: A phase IV,randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity.

ARTEN: Open-label, randomised clinical trial to compare the virological efficacy and safety of Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine vs. Nevirapine on the same background, in HIV-1-infected patients who have received no previous antiretroviral treatment

NEVIRAPINE-TOX: A case-control toxicogenomics study to identify unique genetic polymorphisms in patients who have experienced symptomatic hepatotoxicity or severe cutaneous toxicity within the first 8 weeks of Nevirapine therapy.

TMC125: Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options.

START: (Strategic Timing of AntiRetroviral Treatment):  A large Trial comparing two strategies for the beginning of Anti-Retroviral-Treatment (Multicentrestudy, Sponsor: NIH/USA)

VERVE: Open-label, double blind, randomised clinical trial comparing the antiviral efficacy and safety of the new formulation of nevirapine (nevirapine extended release) given once daily versus the old, current formulation (nevirapine immediate release) given twice daily on a backbone therapy of Emtricitabine and Tenofovir in therapy naïve HIV-1-infected patients

VICRIVIROC: Open-label, randomised, double blind clinical trial comparing therapy experienced HIV infected patients receiving an optimized antiretroviral therapy regimen and Vicriviroc, a CC5 receptor inhibitor, with therapy experienced HIV infected patients receiving an optimized antiretroviral therapy not receiving Vicriviroc